Researcher
Xavier Saelens
- Keywords (Ghent University):antiviral immunity, virology, vaccines
- Disciplines (Flanders Institute for Biotechnology):Analytical biochemistry, Cell death and senescence, Analysis of next-generation sequence data, General diagnostics
- Disciplines (Ghent University):Applied immunology, Drug discovery and development not elsewhere classified, Clinical trials, Biopharmaceuticals, In vitro testing, Non-clinical studies, Animal immunology, Transcription and translation, Vaccines, Molecular and cell biology not elsewhere classified, Virology
- See also: Xavier Saelens (Flanders Institute for Biotechnology)
Affiliations
- Department of Biochemistry and microbiology (Department)
Member
From1 Oct 2018 → Today - Saelens Lab (Research group)
Responsible
From1 Jan 2017 → Today - Department of Biomedical molecular biology (Department)
Member
From1 Jan 1996 → 30 Sep 2018 - Department of Plant Biotechnology and Bioinformatics (Department)
Member
From1 Jan 1993 → 31 Dec 1995
Projects
1 - 10 of 21
- Development of intrabody-expressing influenza virus vectors to discover new pro- and antiviral host factorsFrom1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- New antivirals against human parainfluenza virusFrom1 Apr 2023 → TodayFunding: IOF - technology validation in lab
- Flow imaging microscope for advanced analysis of biopharmaceuticals and biological samplesFrom15 Dec 2022 → TodayFunding: BOF - scientific equipment program
- Prepared for SARS-CoV-3: advancing our understanding of SARS coronavirus antigenic and pathogenic evolutionFrom1 Jan 2022 → TodayFunding: FWO EOS
- A nanobody-based anti-inflammatory treatment against Pseudomonas aeruginosa-induced inflammation in chronic lung diseases.From1 Nov 2021 → TodayFunding: FWO Strategic Basic Research Grant
- A nanobody-based anti-inflammatory treatment against Pseudomonas aeruginosa-induced inflammation in chronic lung diseasesFrom1 Oct 2021 → 31 Oct 2021Funding: BOF - doctoral mandates
- A nanobody-based anti-inflammatory treatment against pathogen-induced chronic lung inflammationFrom1 Oct 2021 → TodayFunding: BOF - projects
- Designed, broadly protective antibodies directed against influenza B.From1 Nov 2020 → TodayFunding: FWO Strategic Basic Research Grant
- mRNA Lipid nanoparticles co-loaded with alpha-Galactosylceramide as a universal influenza vaccine platformFrom1 Oct 2020 → 30 Sep 2022Funding: BOF - postdoctoral mandates
- Prophylaxis of at risks persons with an ultrapotent SARS-CoV-2-neutralizing antibodyFrom22 May 2020 → 31 May 2021Funding: FWO Special Call for Covid-19 research projects
Publications
31 - 39 of 39
- Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against Influenza A virus challenge(2012)
Authors: Hamidreza Hashemi, Somayeh Pouyanfard, Mojgan Bandehpour, Zahra Noroozbabaei, Bahram Kazemi, Xavier Saelens, Talat Mokhtari-Azad
- Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza A virus infection(2012)
Authors: Oxana V Denisova, Laura Kakkola, Lin Feng, Jakob Stenman, Ashwin Nagaraj, Johanna Lampe, Bhagwan Yadav, Tero Aittokallio, Pasi Kaukinen, Tero Ahola, et al.
Pages: 35324 - 35332 - Tailor-made cleavage site attenuates influenza B(2012)
Authors: Xavier Saelens
Pages: 159 - 161 - Assessment of the antiviral properties of recombinant porcine SP-D against various influenza A viruses in vitro(2011)
Authors: Marine LB Hillaire, Martin van Eijk, Stella E van Trierum, Debby van Riel, Xavier Saelens, Roland A Romijn, Wieger Hemrika, Ron AM Fouchier, Thijs Kuiken, Albert DME Osterhaus, et al.
- Role of IFN-α during the acute stage of a swine influenza virus infection(2010)
Authors: Filip Barbé, Xavier Saelens, Debby Braeckmans, François Lefèvre, Kristien Van Reeth
Pages: 172 - 178 - An influenza A vaccine based on tetrameric ectodomain of matrix protein 2(2008)
Authors: Marina De Filette, Wouter Martens, Kenny Roose, Tom Deroo, Frederik Vervalle, Mostafa Bentahir, Joël Vandekerckhove, Walter Fiers, Xavier Saelens
Pages: 11382 - 11387 - The influenza matrix protein 2 as a vaccine target(2008)
Authors: Xavier Saelens
Pages: 167 - 178 - CTA1-M2e-DD: A novel mucosal adjuvant targeted influenza vaccine(2008)
Authors: DG ELIASSON, Karim El Bakkouri, K SCHOEN, A RAMNE, Els Festjens, B LOWENADLER, Walter Fiers, Xavier Saelens, N LYCKE
Pages: 1243 - 1252 - PANDEMIC PREPAREDNESS: TOWARD A UNIVERSAL INFLUENZA VACCINE
Authors: Kenny Roose, Walter Fiers, Xavier Saelens
Pages: 80 - 92
Patents
1 - 9 of 9
- CORONA VIRUS BINDERS (Inventor)
- METHODS OF GENERATING BROADLY PROTECTIVE VACCINE COMPOSITIONS COMPRISING NEURAMINIDASE (Inventor)
- MIXED-LINEAGE KINASE DOMAIN-LIKE PROTEIN IN IMMUNOTHERAPEUTIC CANCER CONTROL (Inventor)
- Anti-influenza antibody (Inventor)
- SINGLE DOMAIN ANTIBODY AGAINST RSV F PROTEIN (Inventor)
- METHODS OF GENERATING BROADLY PROTECTIVE VACCINE COMPOSITIONS COMPRISING NEURAMINIDASE (Inventor)
- MIXED-LINEAGE KINASE DOMAIN-LIKE PROTEIN IN IMMUNOTHERAPEUTIC CANCER CONTROL (Inventor)
- RESPIRATORY SYNCYTICAL VIRUS VACCINE (Inventor)
- Anti-influenza antibody (Inventor)